Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 83

Results For "Import"

1698 News Found

Searchlight Pharma to acquire Miravo Healthcare
News | December 26, 2022

Searchlight Pharma to acquire Miravo Healthcare

Miravo to remain a Canadian controlled and operated company following closing of the transaction


Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Drug Approval | December 20, 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit


Sun Pharmaceutical receives warning letter from USFDA for Halol facility
Drug Approval | December 19, 2022

Sun Pharmaceutical receives warning letter from USFDA for Halol facility

The Halol facility was placed under Import Alert by USFDA.


SRL Diagnostics launches laboratory in Panchkula
News | December 19, 2022

SRL Diagnostics launches laboratory in Panchkula

The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology


Mandaviya inaugurates ICMR-NARFBR in Hyderabad
News | December 19, 2022

Mandaviya inaugurates ICMR-NARFBR in Hyderabad

The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.


NHA releases consultation paper on Operationalising Unified Health Interface
Policy | December 16, 2022

NHA releases consultation paper on Operationalising Unified Health Interface

UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols


Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
Diagnostic Center | December 15, 2022

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study